D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136.5 SEK 1.49% Market Closed
Market Cap: 2.3B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Accounts Payable
kr14.2m
CAGR 3-Years
31%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Accounts Payable
kr49.3m
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Accounts Payable
kr10.4m
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Accounts Payable
kr190m
CAGR 3-Years
62%
CAGR 5-Years
36%
CAGR 10-Years
26%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Accounts Payable
kr1.4B
CAGR 3-Years
20%
CAGR 5-Years
32%
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Accounts Payable
kr29.9m
CAGR 3-Years
28%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.3B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
123.02 SEK
Overvaluation 10%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Accounts Payable?
Accounts Payable
14.2m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Accounts Payable amounts to 14.2m SEK.

What is Devyser Diagnostics AB's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
35%

Over the last year, the Accounts Payable growth was 48%. The average annual Accounts Payable growth rates for Devyser Diagnostics AB have been 31% over the past three years , 35% over the past five years .

Back to Top